Post-earnings recap
Reported
Thu, May 5, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a significant loss per share of $5.39, with no revenue reported. The stock reacted negatively, declining by 2.82%. Investors may be concerned about the lack of financial performance and guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-5.39 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.